Business & Regulation

What lies ahead for the future of pharma? Dennis van Rooji gives his view.

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

Trump withdraws the US from the WHO and pharma stakeholders call for changes to price negotiation program

AI helps make preclinical decisions faster, but stakeholders remain cautious. We asked an expert from Elsevier for their views on the challenges.

AI is not just for the drug development phase of pharmaceutical manufacturing. Now is the time for the business side to leverage it.

New medicines save lives, but they take too long to get to market. Could AI make a difference?

Personalized medicine, digital therapeutics, and GLP-1s; experts tell us what areas are hot in pharma’s future.

Pharma companies are well accustomed to supply chain issues, but how prepared are they for issues impacting access to medical devices?

Celebrate a decade of pharma innovation with The Medicine Maker’s top features, from cancer vaccines to CRISPR breakthroughs.

Summarizing the updated lessons learned by the European Medicines Agency following the COVID-19 pandemic.